Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma

Hong Yang, Simon N. Robinson, Yago Nieto, Richard J Jones, Christopher Gocke, Junjun Lu, Sergio A. Giralt, Roy B. Jones, William K. Decker, Dongxia Xing, David Steiner, Richard E. Champlin, John D. McMannis, Jingjing Ng, Michael W. Thomas, Nina Shah, Borje S. Andersson, Simrit Parmar, Elizabeth J. Shpall

Research output: Contribution to journalArticle

Abstract

Autologous peripheral blood progenitor cell (PBPC) transplantation is the treatment of choice for selected myeloma patients. However, tumor cells contaminating the apheresis product are a potential source of relapse. Here we report a sequential purging strategy targeting mature and immature clonogenic myeloma cell populations in the autograft. Thawed PBPC products of myeloma patients were treated with rituximab to kill CD138-20+ B cells (highly clonogenic immature cells), and bortezomib to target CD138 + cells (normal and differentiated myeloma plasma cells), followed by coculture with allogeneic mesenchymal stem cells (MSC) from normal donors. After 7 days of coculture, nonadherent cells were removed and cultured in the absence of MSC for an additional 7 days. Then, efficacy of purging (removal of CD138-20+ and CD138+ cells) was assessed by flow cytometry and PCR. We used our ex vivo purging strategy to treat frozen aphereses from 16 patients. CD138+ and CD138-20 +(19+) cells present in the initial products were depleted more than 3 and 4 logs, respectively based on 106 flow-acquisition events, and to levels below the limit of detection by PCR. In contrast, total nucleated cell (TNC), CD34+ cell, and colony-forming cell numbers were increased by approximately 12 to 20, 8-, and 23-fold, respectively. Overall, ex vivo treatment of apheresis products with rituximab, bortezomib, and coculture with normal donor MSC depleted mature and immature myeloma cells from clinical aphereses while expanding the normal hematopoietic progenitor cell compartment.

Original languageEnglish (US)
Pages (from-to)5040-5049
Number of pages10
JournalCancer Research
Volume71
Issue number14
DOIs
StatePublished - Jul 15 2011

Fingerprint

Multiple Myeloma
Blood Cells
Stem Cells
Transplants
Blood Component Removal
Coculture Techniques
Mesenchymal Stromal Cells
Tissue Donors
Polymerase Chain Reaction
Cell Transplantation
Autografts
Hematopoietic Stem Cells
Limit of Detection
Flow Cytometry
B-Lymphocytes
Cell Count
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. / Yang, Hong; Robinson, Simon N.; Nieto, Yago; Jones, Richard J; Gocke, Christopher; Lu, Junjun; Giralt, Sergio A.; Jones, Roy B.; Decker, William K.; Xing, Dongxia; Steiner, David; Champlin, Richard E.; McMannis, John D.; Ng, Jingjing; Thomas, Michael W.; Shah, Nina; Andersson, Borje S.; Parmar, Simrit; Shpall, Elizabeth J.

In: Cancer Research, Vol. 71, No. 14, 15.07.2011, p. 5040-5049.

Research output: Contribution to journalArticle

Yang, H, Robinson, SN, Nieto, Y, Jones, RJ, Gocke, C, Lu, J, Giralt, SA, Jones, RB, Decker, WK, Xing, D, Steiner, D, Champlin, RE, McMannis, JD, Ng, J, Thomas, MW, Shah, N, Andersson, BS, Parmar, S & Shpall, EJ 2011, 'Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma', Cancer Research, vol. 71, no. 14, pp. 5040-5049. https://doi.org/10.1158/0008-5472.CAN-11-0842
Yang, Hong ; Robinson, Simon N. ; Nieto, Yago ; Jones, Richard J ; Gocke, Christopher ; Lu, Junjun ; Giralt, Sergio A. ; Jones, Roy B. ; Decker, William K. ; Xing, Dongxia ; Steiner, David ; Champlin, Richard E. ; McMannis, John D. ; Ng, Jingjing ; Thomas, Michael W. ; Shah, Nina ; Andersson, Borje S. ; Parmar, Simrit ; Shpall, Elizabeth J. / Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. In: Cancer Research. 2011 ; Vol. 71, No. 14. pp. 5040-5049.
@article{396686681b37434182c22b82e06de6d7,
title = "Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma",
abstract = "Autologous peripheral blood progenitor cell (PBPC) transplantation is the treatment of choice for selected myeloma patients. However, tumor cells contaminating the apheresis product are a potential source of relapse. Here we report a sequential purging strategy targeting mature and immature clonogenic myeloma cell populations in the autograft. Thawed PBPC products of myeloma patients were treated with rituximab to kill CD138-20+ B cells (highly clonogenic immature cells), and bortezomib to target CD138 + cells (normal and differentiated myeloma plasma cells), followed by coculture with allogeneic mesenchymal stem cells (MSC) from normal donors. After 7 days of coculture, nonadherent cells were removed and cultured in the absence of MSC for an additional 7 days. Then, efficacy of purging (removal of CD138-20+ and CD138+ cells) was assessed by flow cytometry and PCR. We used our ex vivo purging strategy to treat frozen aphereses from 16 patients. CD138+ and CD138-20 +(19+) cells present in the initial products were depleted more than 3 and 4 logs, respectively based on 106 flow-acquisition events, and to levels below the limit of detection by PCR. In contrast, total nucleated cell (TNC), CD34+ cell, and colony-forming cell numbers were increased by approximately 12 to 20, 8-, and 23-fold, respectively. Overall, ex vivo treatment of apheresis products with rituximab, bortezomib, and coculture with normal donor MSC depleted mature and immature myeloma cells from clinical aphereses while expanding the normal hematopoietic progenitor cell compartment.",
author = "Hong Yang and Robinson, {Simon N.} and Yago Nieto and Jones, {Richard J} and Christopher Gocke and Junjun Lu and Giralt, {Sergio A.} and Jones, {Roy B.} and Decker, {William K.} and Dongxia Xing and David Steiner and Champlin, {Richard E.} and McMannis, {John D.} and Jingjing Ng and Thomas, {Michael W.} and Nina Shah and Andersson, {Borje S.} and Simrit Parmar and Shpall, {Elizabeth J.}",
year = "2011",
month = "7",
day = "15",
doi = "10.1158/0008-5472.CAN-11-0842",
language = "English (US)",
volume = "71",
pages = "5040--5049",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma

AU - Yang, Hong

AU - Robinson, Simon N.

AU - Nieto, Yago

AU - Jones, Richard J

AU - Gocke, Christopher

AU - Lu, Junjun

AU - Giralt, Sergio A.

AU - Jones, Roy B.

AU - Decker, William K.

AU - Xing, Dongxia

AU - Steiner, David

AU - Champlin, Richard E.

AU - McMannis, John D.

AU - Ng, Jingjing

AU - Thomas, Michael W.

AU - Shah, Nina

AU - Andersson, Borje S.

AU - Parmar, Simrit

AU - Shpall, Elizabeth J.

PY - 2011/7/15

Y1 - 2011/7/15

N2 - Autologous peripheral blood progenitor cell (PBPC) transplantation is the treatment of choice for selected myeloma patients. However, tumor cells contaminating the apheresis product are a potential source of relapse. Here we report a sequential purging strategy targeting mature and immature clonogenic myeloma cell populations in the autograft. Thawed PBPC products of myeloma patients were treated with rituximab to kill CD138-20+ B cells (highly clonogenic immature cells), and bortezomib to target CD138 + cells (normal and differentiated myeloma plasma cells), followed by coculture with allogeneic mesenchymal stem cells (MSC) from normal donors. After 7 days of coculture, nonadherent cells were removed and cultured in the absence of MSC for an additional 7 days. Then, efficacy of purging (removal of CD138-20+ and CD138+ cells) was assessed by flow cytometry and PCR. We used our ex vivo purging strategy to treat frozen aphereses from 16 patients. CD138+ and CD138-20 +(19+) cells present in the initial products were depleted more than 3 and 4 logs, respectively based on 106 flow-acquisition events, and to levels below the limit of detection by PCR. In contrast, total nucleated cell (TNC), CD34+ cell, and colony-forming cell numbers were increased by approximately 12 to 20, 8-, and 23-fold, respectively. Overall, ex vivo treatment of apheresis products with rituximab, bortezomib, and coculture with normal donor MSC depleted mature and immature myeloma cells from clinical aphereses while expanding the normal hematopoietic progenitor cell compartment.

AB - Autologous peripheral blood progenitor cell (PBPC) transplantation is the treatment of choice for selected myeloma patients. However, tumor cells contaminating the apheresis product are a potential source of relapse. Here we report a sequential purging strategy targeting mature and immature clonogenic myeloma cell populations in the autograft. Thawed PBPC products of myeloma patients were treated with rituximab to kill CD138-20+ B cells (highly clonogenic immature cells), and bortezomib to target CD138 + cells (normal and differentiated myeloma plasma cells), followed by coculture with allogeneic mesenchymal stem cells (MSC) from normal donors. After 7 days of coculture, nonadherent cells were removed and cultured in the absence of MSC for an additional 7 days. Then, efficacy of purging (removal of CD138-20+ and CD138+ cells) was assessed by flow cytometry and PCR. We used our ex vivo purging strategy to treat frozen aphereses from 16 patients. CD138+ and CD138-20 +(19+) cells present in the initial products were depleted more than 3 and 4 logs, respectively based on 106 flow-acquisition events, and to levels below the limit of detection by PCR. In contrast, total nucleated cell (TNC), CD34+ cell, and colony-forming cell numbers were increased by approximately 12 to 20, 8-, and 23-fold, respectively. Overall, ex vivo treatment of apheresis products with rituximab, bortezomib, and coculture with normal donor MSC depleted mature and immature myeloma cells from clinical aphereses while expanding the normal hematopoietic progenitor cell compartment.

UR - http://www.scopus.com/inward/record.url?scp=79960385474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960385474&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-0842

DO - 10.1158/0008-5472.CAN-11-0842

M3 - Article

C2 - 21646477

AN - SCOPUS:79960385474

VL - 71

SP - 5040

EP - 5049

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 14

ER -